

Reportable Diagnosis List from SEER PROGRAM CODING AND STAGING MANUAL 2025

Definition of Reportable: Meets the criteria for inclusion in a registry. Reportable cases are cases that the registry is required to collect and report. Reporting requirements for SEER registries are established by NCI SEER. A "Reportable List" includes all diagnoses to be reported by the registry to NCI SEER.

1. Malignant Histologies (In Situ and Invasive)

- a. Report all histologies with a behavior code of /2 or /3 in the ICD-O-Third Edition, Second Revision Morphology (ICD-O-3.2), except as noted in section 1.b. below. The following are reportable diagnoses that are either new or are frequently questioned.
 - i. Post Transplant Lymphoproliferative Disorder (PTLD) 9971/1 is reportable as 9971/3 as of 01/01/2025
 - ii. High-grade astrocytoma with piloid features (HGAP) (9421/3) as of 01/01/2023
 - iii. Lymphangioleiomyomatosis (9174/3) is reportable as of 01/01/2023; behavior changed from /1 to /3
 - iv. Mesothelioma in situ (9050/2) is reportable as of 01/01/2023
 - v. Diffuse leptomeningeal glioneuronal tumor (9509/3) is reportable as of 01/01/2023
 - vi. The following diagnoses are reportable (not a complete list)
 - Lobular carcinoma in situ (LCIS) of breast
 - Intraepithelial neoplasia, high grade, grade II, grade III
 - Examples: (Not a complete list. See ICD-O-3.2
 - Anal intraepithelial neoplasia II (AIN II) of the anus or anal canal (C210-C211)

Adamo M, Groves C. (January 2025). SEER Program Coding and Staging Manual 2025. National Cancer Institute, Bethesda, MD 20892. U.S. Department of Health and Human Services National Institutes of Health National Cancer Institute

- Anal intraepithelial neoplasia III (AIN III) of the anus or anal canal (C210-C211)
- Biliary intraepithelial neoplasia, high grade
- Conjunctival intraepithelial neoplasia with severe dysplasia, or Grade III; squamous intraepithelial neoplasia Grade II of conjunctiva
- Differentiated vulvar intraepithelial neoplasia (VIN) or differentiated exophytic vulvar intraepithelial lesion (DEVIL)
- Endometrioid intraepithelial neoplasia (atypical hyperplasia, EIN)
- Esophageal intraepithelial neoplasia (dysplasia), high grade or Grade III
- Glandular intraepithelial neoplasia, high grade
- High grade dysplasia of esophagus, stomach, small intestine
- High grade squamous dysplasia of larynx
- High grade squamous intraepithelial lesion (HGSIL) of the anus
- High grade vulvar intraepithelial neoplasia
- Intraductal papillary neoplasm with high grade intraepithelial neoplasia
- Intraepithelial neoplasia, grade III
- Laryngeal intraepithelial neoplasia II (LIN II) (C320-C329)
- Laryngeal intraepithelial neoplasia III (LIN III) (C320-C329)
- Lobular neoplasia grade II (LN II)/lobular intraepithelial neoplasia grade II (LIN II) breast (C500-C509)
- Lobular neoplasia grade III (LN III)/lobular intraepithelial neoplasia grade III (LIN III) breast (C500-C509)
- Pancreatic intraepithelial neoplasia (PanIN III) (C250-C259)
- Penile intraepithelial neoplasia, grade II (PeIN II) (C600-C609)
- Penile intraepithelial neoplasia, grade III or high grade dysplasia (PelN III) (C600-C609)
- Squamous intraepithelial neoplasia, grade II excluding cervix (C53_) and skin sites coded to C44_
- Squamous intraepithelial neoplasia III (SIN III) excluding cervix (C53_) and skin sites coded to C44_
- Vaginal intraepithelial neoplasia II (VAIN II) (C529)
- Vaginal intraepithelial neoplasia III (VAIN III) (C529)
- Vulvar intraepithelial neoplasia II (VIN II) (C510-C519)
- b. Do not report (Exceptions to reporting requirements)
 - Skin primary (C440-C449) with any of the following histologies
 - Malignant neoplasm (8000-8005)

i.

Adamo M, Groves C. (January 2025). SEER Program Coding and Staging Manual
 2025. National Cancer Institute, Bethesda, MD 20892. U.S. Department of Health
 and Human Services National Institutes of Health National Cancer Institute

- Epithelial carcinoma (8010-8046)
- Papillary and squamous cell carcinoma (SCC) (8050-8086)
- Squamous intraepithelial neoplasia III (SIN III) (8077) of skin sites coded to C44_
- Basal cell carcinoma (8090-8110)
- **Note 1:** If the registry collects basal or squamous cell carcinoma of skin sites
- (C440-C449), sequence them in the 60-87 range and do not report to SEER.
- Note 2: SCC of sites coded to C44 (for example, C442 located in the head or neck)
- is not reportable. Do not use AJCC staging to determine reportability.
 Follow
- cancer registry instructions for reportability.

ii. **In situ** carcinoma of **cervix** (/2), any histology, cervical intraepithelial neoplasia

- (CIN III), or SIN III of the cervix (C530-C539)
- Note: Collection stopped effective with cases diagnosed 01/01/1996 and later. As
- of the 2018 data submission, cervical in situ cancer is no longer required for any
- diagnosis year. Sequence all cervix in situ cases in the 60-87 range regardless of
- diagnosis year.

iii. Prostatic intraepithelial neoplasia (PIN II and PIN III) (C619)

Adamo M, Groves C. (January 2025). SEER Program Coding and Staging Manual
 2025. National Cancer Institute, Bethesda, MD 20892. U.S. Department of Health
 and Human Services National Institutes of Health National Cancer Institute

• *Note*: Collection **stopped** effective with cases diagnosed 01/01/2001 and later.

iv. Colon atypical hyperplasia

v. High grade dysplasia in colorectal sites (C180-C189, C199, and C209)

vi. Adenocarcinoma in situ, HPV associated (8483/2)(C53)

Refer to Appendix E.2 for non-reportable examples.

2. Benign/Non-Malignant Histologies

a. Report benign and borderline primary intracranial and central nervous system (CNS) tumors with a behavior code of /0 or /1 in ICD-O-3 (effective with cases diagnosed 01/01/2004 to 12/31/2020) or ICD-O-3.2 (effective with cases diagnosed 01/01/2021 and later). See the table below for the specific sites.

Note 1: Benign and borderline tumors of the cranial bones (C410) are **not reportable**.

Note 2: Benign and borderline tumors of the peripheral nerves (C47_) are

not reportable.

- Report pilocytic astrocytoma/juvenile pilocytic astrocytoma as 9421/1 for all CNS sites as of 01/01/2023
- c. Report diffuse astrocytoma, MYB- or MYBL1-altered and diffuse low-grade glioma, MAPK pathway-altered (9421/1) as of 01/01/2023
- d. Report multinodular and vacuolating neuronal tumor (9509/0) as of 01/01/2023
- e. Report juvenile xanthogranuloma (9749/1) as of 01/01/2023 (C715 is the most common site)
- f. **Neoplasm and tumor** are reportable terms for intracranial and CNS because they are listed in ICD-O-3.2 with behavior codes of /0 and /1
 - "Mass" and "lesion" are not reportable terms for intracranial and CNS because they are not listed in ICD-O-3.2 with behavior codes of /0 or /1

Adamo M, Groves C. (January 2025). SEER Program Coding and Staging Manual 2025. National Cancer Institute, Bethesda, MD 20892. U.S. Department of Health and Human Services National Institutes of Health National Cancer Institute